Fair Value Calculator Fair Value Calculator
EN DE

MARKOLINES (MARKOLINES) Fair Value & Analysis

IN · Market cap ₹4.1B

M MARKOLINES MARKOLINES · BSE
Price₹187.95
Fair Value₹195.10
Upside+3.8%
Quality56/100
Watch MARKOLINES for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹104.25 – ₹257.96

Fair value as of: Jul 5, 2026

From 25 valuation models · updated today

Share price +14.6% over the past month.

Price vs Fair Value (12 months)

₹188.15 ₹120.28 Fair Value ₹195.10 Jun 2025 Jul 2026

12‑month range ₹120.28 – ₹188.15 · fair‑value band ₹104.25 – ₹257.96 · the ₹187.95 price screens below the ₹195.10 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

MARKOLINES (MARKOLINES) currently trades at ₹187.95, while our model-based Fair Value estimate is ₹195.10 — implying the stock looks roughly 3.8% undervalued today. We read business quality at 56/100 (solid quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, MARKOLINES generated revenue of ₹3.5B at a net margin of 7.5%. Revenue declined 13.5% year over year. It earns a return on equity of 13.8%. Net debt stands at ₹843M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹104.25 (bear case) to ₹257.96 (bull case); at ₹187.95, the current price sits within that range. The share trades about 2% below its 52-week high and 58% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹3.5B
Revenue growth (YoY) -13.5%
Net margin 7.5%
Return on equity 13.8%
Free cash flow ₹8.9M FY2026
P/E ratio 15.8
More key figures
Operating margin 16.2%
EPS (TTM) ₹11.90
EPS growth (YoY) -4.6%
Net debt ₹843M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

MARKOLINES reported revenue of ₹3.5B in FY2026 versus ₹1.5B in FY2022, a compound +23.9%/yr. Reported net income was ₹262M in FY2026, compounding +26.9%/yr from FY2022.

Revenue +23.9%/yr
FY22 ₹1.5B
FY23 ₹2.7B
FY24 ₹3.3B
FY25 ₹3.1B
FY26 ₹3.5B
Net income +26.9%/yr
FY22 ₹101M
FY23 ₹157M
FY24 ₹173M
FY25 ₹227M
FY26 ₹262M

Is MARKOLINES fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "MARKOLINES Fair Value". https://www.fairvalue-calculator.com/stock/MARKOLINES

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is MARKOLINES (MARKOLINES) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹195.10 versus a price of ₹187.95 — about +4% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MARKOLINES?
Our model-based fair value for MARKOLINES is ₹195.10 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹187.95.
What is the quality score of MARKOLINES?
MARKOLINES has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of MARKOLINES (MARKOLINES)?
MARKOLINES reported trailing-twelve-month revenue of about ₹3.5B (latest available figure, as of Jul 5, 2026).
What is the net profit margin of MARKOLINES?
The net profit margin of MARKOLINES is about 7.5%, meaning it keeps roughly 7.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.